Follicular Lymphoma Treatment Market Report 2026

Follicular Lymphoma Treatment Market Overview

• Follicular Lymphoma Treatment market size has reached to $3.28 billion in 2025 • Expected to grow to $4.91 billion in 2030 at a compound annual growth rate (CAGR) of 8.5% • Growth Driver: Follicular Lymphoma Treatment Market Surges Amidst Growing Prevalence • Market Trend: Chugai Pharmaceutical Introduces Bispecific Antibody Breakthrough In Follicular Lymphoma Treatment • North America was the largest region in 2025.

What Is Covered Under Follicular Lymphoma Treatment Market?

Follicular lymphoma treatment refers to the medical interventions and therapies aimed at managing and combating the progression of follicular lymphoma, a type of non-Hodgkin lymphoma characterized by abnormal cell growth in the lymphatic system. The medication is often administered into a vein (intravenously). Radiation therapy can be used to treat early-stage follicular lymphoma. The main types treatments of follicular lymphoma treatment are monoclonal antibodies, targeted therapy, chemotherapy, radiation therapy, stem cell transplant, alkylating agents, nucleoside analogues, anthracycline derivatives, and others. Monoclonal antibodies refer to laboratory-produced proteins designed to mimic the immune system's ability to target specific substances in the body. It is used in follicular lymphoma treatment to target specific proteins on the surface of cancer cells and stimulate the immune system's response. The various products of follicular lymphoma treatment include tablets, capsules, injectables, and others that are administered through oral, parenteral, and other route of administration provided in hospitals, oncology centers, ambulatory care centers, academic research institutes, and others.

What Is The Follicular Lymphoma Treatment Market Growth Forecast?

The follicular lymphoma treatment market size is expected to see strong growth in the next few years. It will grow to $4.91 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to innovation in targeted therapy, integration of ai in treatment planning, growth in stem cell transplant procedures, expansion of oncology centers in emerging markets, development of biosimilars. Major trends in the forecast period include personalized treatment protocols, development of novel monoclonal antibodies, combination therapy approaches, early diagnosis and screening initiatives, minimally invasive treatment techniques.

Global Follicular Lymphoma Treatment Market Segmentation

1) By Treatment: Monoclonal Antibodies, Targeted Therapy, Chemotherapy, Radiation Therapy, Stem Cell Transplant, Alkylating Agents 2) By Product Type: Tablets, Capsules, Injectables, Other Product Types 3) By Route of Administration: Oral, Parenteral, Other Route of Administration 4) By End Use: Hospitals, Oncology Centers, Ambulatory Care Centers, Academic Research Institutes, Other End Users Subsegments: 1) By Monoclonal Antibodies: Rituximab, Obinutuzumab, Ofatumumab 2) By Targeted Therapy: PI3K Inhibitors, BTK Inhibitors, BCL-2 Inhibitors 3) By Chemotherapy: CHOP Regimen, Bendamustine, Fludarabine 4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Radioimmunotherapy 5) By Stem Cell Transplant: Autologous Stem Cell Transplant, Allogeneic Stem Cell Transplant 6) By Alkylating Agents: Cyclophosphamide, Ifosfamide

What Is The Driver Of The Follicular Lymphoma Treatment Market?

The rising prevalence of follicular lymphoma is expected to propel the growth of the follicular lymphoma treatment market moving forward. The prevalence of follicular lymphoma refers to the total number or proportion of individuals within a specific population diagnosed with follicular lymphoma at a given time or over a particular period. This shift has resulted from the rise in the aging population, genetic predisposition, improved diagnostic techniques, and increased awareness and screening. Follicular lymphoma treatment helps reduce the prevalence of follicular lymphoma by addressing the disease at various stages and aids in disease treatment and progression. The rise in the incidence of follicular lymphoma is boosting the growth of the follicular lymphoma treatment market. For instance, in January 2023, according to the American Cancer Society, a US-based Voluntary organization, non-Hodgkin lymphoma, a type of indolent follicular lymphoma, is the most frequent cancer in the US, accounting for around 4% of all cancers. The American Cancer Society projects that NHL will be diagnosed in approximately 80,550 persons (44,880 men and 35,670 women). This includes both adults and children. Therefore, the rising prevalence of follicular lymphoma is driving the growth of the follicular lymphoma treatment industry.

Key Players In The Global Follicular Lymphoma Treatment Market

Major companies operating in the follicular lymphoma treatment market are AbbVie Inc., Bayer AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson and Johnson Services Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co. Inc., Boehringer Ingelheim GmbH, CTI BioPharma Corp., Spectrum Pharmaceuticals Inc., Seattle Genetics Inc., Daiichi Sankyo Company Ltd., Pfizer Inc., Incyte Corporation, MorphoSys AG, Regeneron Pharmaceuticals Inc., Eli Lilly and Company, Seagen Inc., Takeda Pharmaceutical Company, Nordic Nanovector ASA, ADC Therapeutics SA, MEI Pharma Inc., BeiGene Inc., TG Therapeutics Inc., Amgen Inc.

Global Follicular Lymphoma Treatment Market Trends and Insights

Major companies operating in the follicular lymphoma treatment market are focusing on developing advanced solutions such as bispecific antibodies to enhance durable remission and reduce patient treatment burden. A bispecific antibody is a molecule engineered to simultaneously bind two different targets for example, one arm binds a tumor antigen on B cells and the other engages T cells thereby redirecting the immune system to kill cancer cells more efficiently. For instance, in March 2025, Chugai Pharmaceutical, a Japan-based research-driven oncology company, launched LUNSUMIO, featuring a CD20/CD3 bispecific antibody system. LUNSUMIO is approved as an intravenous infusion in 1 mg and 30 mg formulations. It is intended for patients with relapsed or refractory follicular lymphoma who have failed at least two prior standard therapies. The therapy is designed for fixed-duration treatment based on individual patient response, which can reduce long-term treatment burden. LUNSUMIO has demonstrated high complete response rates and has the potential to deliver durable remission as a monotherapy.

What Are Latest Mergers And Acquisitions In The Follicular Lymphoma Treatment Market?

In December 2024, Innate Pharma, a France-based developer of immunotherapy-based cancer treatments, partnered with the Institute for Follicular Lymphoma Innovation (IFLI) to support the clinical development of its IPH6501 program. With this partnership, Innate Pharma aims to accelerate the development of its ANKET-based bispecific immunotherapy in relapsed/refractory follicular lymphoma patients by leveraging IFLI’s dedicated funding and lymphoma-focused expertise. Follicular Lymphoma Innovation (IFLI) is a US-based research organization committed to investing in and advancing follicular lymphoma treatments through both financial and scientific collaboration.

Regional Insights

North America was the largest region in the follicular lymphoma treatment market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Follicular Lymphoma Treatment Market?

The follicular lymphoma treatment market includes revenues earned by entities by providing drugs, medications, diagnostic devices, radiation therapy equipment, surgical instruments, and devices. Therapies that are used in the treatment of follicular lymphoma. The follicular lymphoma treatment market includes surgery, radiation therapy, chemotherapy, hormonal therapy, targeted therapy, and supportive care.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Follicular Lymphoma Treatment Market Report 2026?

The follicular lymphoma treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the follicular lymphoma treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.